Global Search

Hide Filters

Showing 1672 results

Press release / May 12, 2018

Novartis announces FDA approval of Gilenya® as the first disease-modifying therapy for pediatric relapsing multiple sclerosis

New approval for Gilenya (fingolimod) addresses strong unmet need for younger patients, who often experience more frequent relapses than adults with multiple sclerosis (MS)[1] In a…
Press release / Feb 08, 2018

Novartis receives FDA approval for Cosentyx® label update to include moderate-to-severe scalp psoriasis

US label updated to include Cosentyx® (secukinumab) data in moderate-to-severe scalp psoriasis[1] - one of the difficult-to-treat types of psoriasis[2] Approximately half of all 125 million…
Press release / Jan 15, 2016

Novartis receives two new FDA approvals for Cosentyx to treat patients with ankylosing spondylitis and psoriatic arthritis in the US

Cosentyx is the first and only interleukin-17A (IL-17A) inhibitor approved for adult patients with ankylosing spondylitis (AS) and psoriatic arthritis (PsA) FDA approval for Cosentyx is…
Press release / Nov 08, 2015

Novartis presents new two year data for Cosentyx® showing no progression in joint damage in 84% of psoriatic arthritis patients

New x-ray assessment data, from a sub-study, showed no progression of joint structural damage in the majority of patients with psoriatic arthritis over two years[1] Psoriatic arthritis patients on…
Press release / Nov 08, 2015

New two year data for Novartis' Cosentyx® show sustained response and no progression in spinal damage as shown by x-ray in up to 80% of patients with ankylosing spondylitis

A sub-study showed up to 80% of ankylosing spondylitis (AS) patients treated with Cosentyx had no radiographic progression in the spine over two years[1] Cosentyx demonstrated a sustained…
Ad hoc release / Mar 28, 2025

FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer

Ad hoc announcement pursuant to Art. 53 LR New indication approximately triples eligible patient population, allowing Pluvicto® to be used after one androgen receptor pathway inhibitor (ARPI)…
Press release / Jul 20, 2021

Novartis pledges 10-year commitment with Morehouse School of Medicine, 26 Historically Black Colleges, Universities, Medical Schools and other leading organizations to co-create effective, measurable solutions for health equity

Novartis and the Novartis US Foundation to join forces with Thurgood Marshall College Fund, Morehouse School of Medicine, 26 other Historically Black Colleges, Universities and Medical Schools and…
Press release / Oct 28, 2020

Novartis announces collaboration with Molecular Partners to develop two DARPin® therapies designed for potential use against COVID-19

Novartis has been granted an option to in-license global rights of MP0420 and MP0423 - multi-targeted direct acting antiviral therapeutic candidates demonstrating potential efficacy against COVID-…
Press release / Feb 26, 2021

Novartis Cosentyx® gains EU label update for first-of-its-kind MAXIMISE data in axial manifestations of psoriatic arthritis

Cosentyx® (secukinumab) is the first biologic with proven efficacy in all 6 key manifestations of psoriatic arthritis (PsA), and the only biologic with fast and lasting relief of axial manifestations…
Ad hoc release / Nov 24, 2019

Novartis to acquire The Medicines Company for USD 9.7 bn, adding inclisiran, a potentially transformational investigational cholesterol-lowering therapy to address leading global cause of death

Over 50 million secondary prevention patients worldwide with atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia (FH) on current standard of care do not achieve LDL…

‹ Previous page
1
…
27
28
29
30
31
32
33
…
168
› Next page